Regeneron Pharmaceuticals Inc (BSP:REGN34)
R$ 89.25 1.25 (1.42%) Market Cap: 590.31 Bil Enterprise Value: 549.72 Bil PE Ratio: 24.59 PB Ratio: 3.63 GF Score: 86/100

Regeneron Pharmaceuticals Inc Oncology Investor Event, ASCO 2020 Transcript

Jun 01, 2020 / 08:30PM GMT
Release Date Price: R$53.6 (+4.27%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Regeneron Oncology Investor Event, ASCO 2020. (Operator Instructions) And please be advised that today's conference is being recorded.

Now it's my pleasure to turn the call to the Vice President of Investor Relations, Mr. Justin Holko.

Justin Holko
Regeneron Pharmaceuticals, Inc. - VP of IR

Thank you, Carmen, and welcome, everyone, to Regeneron's first ever ASCO investor webcast. Joining me today are Dr. George Yancopoulos, Co-Founder, President and Chief Scientific Officer; Marion McCourt, Senior Vice President and Head of Commercial; Dr. David Weinreich, Senior Vice President and Head of Global Clinical Development; Dr. Israel Lowy, Senior Vice President of Translational Sciences and Oncology; and Dr. Andres Sirulnik, Senior Vice President, Translation and Clinical Science Hematology.

After our prepared remarks, we will open the call for Q&A. Before handing the call over to George, I would like to remind you that remarks made on today's call include forward-looking

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot